About Cencora Inc
- Industry: Health Care
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.cencora.com/
Frequently Asked Questions
What is the 52-week range for COR?
The 52-week high is $377.54 and the 52-week low is $244.82.
What is the P/E ratio for COR?
The Price to Earnings (P/E) ratio is 22.42.
What is the dividend yield for COR?
The indicated annual dividend yield is 1.01%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 106.43%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 0.79%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 40.18.
Analyst Recommendation Trends
Wall Street analyst consensus for COR over the last few months:
Latest COR News
Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
CONSHOHOCKEN, Pa., October 02, 2026--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 4, 2026.
2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.
Cardinal Health: I'm Still Buying After Checking The Numbers
Cardinal Health remains a Buy, driven by robust FY2026 results, strong cash flow, and credible FY2027 guidance. Read more on CAH stock here.
Wednesday's session: gap up and gap down stock in the S&P500 index
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.
$100 Invested In Cencora 5 Years Ago Would Be Worth This Much Today
Cencora (NYSE:COR) has outperformed the market over the past 5 years by 8.44% on an annualized basis producing an average annual return of 20.45%. Currently, Cencora has a market capitalization of $57.98 billion.
1 of Wall Street’s Favorite Stocks with Impressive Fundamentals and 2 We Turn Down
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.
Cencora Elects Robert E. Sanchez to Its Board of Directors
CONSHOHOCKEN, Pa., September 25, 2026--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026.
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.
Can CAH's MSO Expansion Unlock Growth in Specialty Care Delivery?
CAH is expanding its MSO strategy across specialty care, with Solaris and broader services aimed at scaling physician networks.
Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027
Cencora (NYSE:COR) executives said the company expects its specialty-focused strategy to support continued growth into fiscal 2027, citing demand in oncology and retina, expanded physician-services capabilities and momentum in its international businesses. Speaking at the Morgan Stanley Global Heal
Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference
Cencora (NYSE:COR) executives highlighted the company’s specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens. Chief Executive Offi
Cencora (COR) Lifts EPS Outlook And Buyback, Is The Stock Still Below Fair Value?
Cencora (COR) just combined a stronger fiscal third quarter, a higher full year adjusted EPS outlook, and a US$1b buyback with plans to brief investors at two New York healthcare conferences. Despite the upbeat earnings message, Cencora’s share price has eased in the short term, with a 7 day share price return of down 3.98% and a 30 day share price return of down 2.91% from US$308.78. At the same time, a 90 day share price return of 13.82% and a 1 year total shareholder return of 7.28% sit...
Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch?
On August 5, Cencora (NYSE:COR) reported results for its fiscal third quarter, which closed on June 30, and the headline numbers looked clean. Revenue rose 5.1% to $84.8 billion, adjusted earnings per share climbed 12.0% to $4.48, and management raised its full-year adjusted EPS outlook to $17.75 to $17.95. The company also repurchased $1 billion […]
Cencora Tech Chief: AI Is Cutting Some Medical Treatment Decisions in Half
Cencora Global Chief Data and Information Officer Pawan Verma spoke with WSJ Leadership Institute President Alan Murray at the WSJLI Technology Council Summit about how AI is being used in healthcare to speed access to treatment. Verma described a retinal oncology use case in which doctors analyze large volumes of imaging data to determine treatment, saying Cencora is helping cut a decision process that can take 30 to 90 days roughly in half.
Cencora, Inc. (COR) Presents at 2026 Global Healthcare Conference Transcript
Cencora, Inc. (COR) 2026 Global Healthcare Conference September 15, 2026 3:10 PM EDTCompany ParticipantsEva Boratto - Executive VP & CFORobert Mauch -...
The Realities of Managing Enterprise AI
A panel of CIOs from Indeed, New York Life and Cencora discuss the risks and advantages of enterprise AI, including operational efficiency, financial waste and the need to implement “control towers” for human oversight of consequential decisions.
Cencora, Inc. (COR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Cencora, Inc. (COR) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 8:30 AM EDTCompany ParticipantsRobert Mauch - President, CEO...
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.
Coultreon Biopharma Appoints Nate Massari as Chief Business Officer
Nate Massari’s business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis and Crohn’s disease, will support the advancement of Coultreon's first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. September 14, 2026. Coultreon Biopharma, a clinical-stage biotechnology company developing best-in-class immunology therapies, today announced the appointment of Nate Massari as Chief Business Officer. Nate brings more than 25 years of expe
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.
Cencora (NYSE:COR): A Quality Stock With Strong EBIT Growth and Cash Conversion
Cencora (COR) scores well on EBIT growth, cash-backed profits and debt/FCF, but thin margins and high debt/equity warrant caution for quality investors.
CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue?
Cardinal Health's 29% rally reflects stronger specialty growth, MSO expansion and higher-margin assets, but cost pressures could test the uptrend.
$1000 Invested In Cencora 10 Years Ago Would Be Worth This Much Today
Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.79% on an annualized basis producing an average annual return of 20.35%. Currently, Cencora has a market capitalization of $61.36 billion.
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
2 S&P 500 Stocks with Exciting Potential and 1 We Question
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
Is Cencora Stock Underperforming the Dow?
Despite lagging behind the Dow over the past 12 months, Cencora continues to receive a highly bullish outlook from Wall Street analysts.
Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Cencora (NYSE:COR) and its peers.
Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Cencora, Inc. (COR) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 9:30 AM EDTCompany ParticipantsRobert Mauch - President, CEO &...
RBC Capital Reiterates Sector Perform on Cencora, Maintains $330 Price Target
RBC Capital analyst Ryan Halsted reiterates Cencora (NYSE:COR) with a Sector Perform and maintains $330 price target.
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?
Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cencora Launches Cell and Gene Therapy Enablement for Health Systems
COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.
Is Cencora (COR) Still Undervalued On Higher 2026 Guidance And Strong Q3 Earnings?
Cencora (COR) drew investor attention after third quarter results showed adjusted earnings per share of US$4.48, up 12% year over year, along with a higher fiscal 2026 adjusted earnings outlook. Cencora's latest earnings beat and higher 2026 guidance come after a strong run, with the share price up 22.6% over 90 days and a 1 year total shareholder return of 16.1%, building on a 5 year total shareholder return of 186.8%. Capitalize on Cencora's earnings momentum by scanning a hand picked group...
What Cencora (COR)'s Cell and Gene Push and Higher 2026 Outlook Means For Shareholders
Cencora recently launched its Cell and Gene Therapy Enablement service through Accelerate Pharmacy Solutions to help health systems evaluate, build and scale advanced therapy programs, while also raising its fiscal 2026 adjusted earnings outlook following stronger-than-expected third-quarter results. The combination of expanded capabilities in cell and gene therapies and faster profit growth across its healthcare solutions segments highlights how Cencora is deepening its role in complex,...
Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”
On the September 2 episode of Mad Money, Jim Cramer called Cardinal Health, Inc. (NYSE:CAH) one of his “absolute favorites” and mentioned its growing exposure to specialty pharmaceuticals and higher-margin healthcare services. Cardinal’s been running circles around McKesson and Cencora. They consistently put up the best numbers because this company has gradually become less of […]
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen
Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.
Is Generics Still a Quiet Profit Engine for Cardinal Health?
Cardinal Health's generic volumes, profitable brand-to-generic conversions and Red Oak program continue to support Pharma profits.
Artisan Sold Cencora (COR) as Earnings Momentum Slowed
Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the “Artisan Global Opportunities Strategy”. The letter can be downloaded here. Global equities rebounded sharply during the quarter, with the MSCI ACWI Index returning 15.3% as resilient economic growth, strong corporate earnings, and continued enthusiasm around artificial intelligence supported markets despite persistent inflation, […]
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-16 | GREENBERG LON R | -1,280 | $321.3 | $411,264 |
| 2026-09-01 | Krikorian Lazarus | -985 | $325.97 | $321,080 |
| 2026-08-24 | Campbell Elizabeth S | -11,300 | $324.116 | $3,662,511 |
| 2026-07-31 | Tyler Lauren M | +97 | $311.34 | $30,200 |
| 2026-07-31 | NALLY DENNIS M | +113 | $311.34 | $35,181 |
| 2026-07-31 | Cooper Ellen | +97 | $311.34 | $30,200 |
| 2026-06-30 | Campbell Elizabeth S | +50 | $240.533 | $12,027 |
| 2026-06-30 | Battaglia Silvana | +58 | $240.533 | $13,951 |
| 2026-06-22 | Tyler Lauren M | +550 | $270.23 | $148,627 |
| 2026-06-18 | DURCAN DERMOT MARK | +4,000 | $274.19 | $1,096,760 |
| 2026-05-28 | DURCAN DERMOT MARK | +4,000 | $266.26 | $1,065,040 |
| 2026-05-01 | Tyler Lauren M | +99 | $304 | $30,096 |
| 2026-05-01 | NALLY DENNIS M | +116 | $304 | $35,264 |
| 2026-05-01 | Cooper Ellen | +99 | $304 | $30,096 |
| 2026-04-01 | Krikorian Lazarus | +3,936 | - | - |
| 2026-03-11 | Campbell Elizabeth S | -12,623 | - | - |
| 2026-03-11 | Campbell Elizabeth S | -5,842 | $350.3 | $2,046,453 |
| 2026-03-11 | Campbell Elizabeth S | +12,623 | - | - |
| 2026-03-11 | Battaglia Silvana | -8,415 | - | - |
| 2026-03-11 | Battaglia Silvana | -3,673 | $350.3 | $1,286,652 |
| 2026-03-11 | Battaglia Silvana | +8,415 | - | - |
| 2026-03-11 | Cleary James F | -12,623 | - | - |
| 2026-03-11 | Cleary James F | -5,409 | $350.3 | $1,894,773 |
| 2026-03-11 | Cleary James F | +12,623 | - | - |
| 2026-03-05 | Baumann Werner | +557 | $359.28 | $200,119 |
| 2026-03-05 | Miller Redonda | +557 | $359.28 | $200,119 |
| 2026-03-05 | Tyler Lauren M | +557 | $359.28 | $200,119 |
| 2026-03-05 | Clyburn Frank | +557 | $359.28 | $200,119 |
| 2026-03-05 | NALLY DENNIS M | +557 | $359.28 | $200,119 |
| 2026-03-05 | Kim Lorence H. | +557 | $359.28 | $200,119 |
| 2026-03-05 | Cooper Ellen | +557 | $359.28 | $200,119 |
| 2026-03-05 | Ryerkerk Lori | +557 | $359.28 | $200,119 |
| 2026-03-05 | GREENBERG LON R | +557 | $359.28 | $200,119 |
| 2026-03-05 | DURCAN DERMOT MARK | +905 | $359.28 | $325,148 |
| 2026-02-20 | Mauch Robert P. | -3,762 | - | - |
| 2026-02-20 | Mauch Robert P. | -3,762 | $358.94 | $1,350,332 |
| 2026-02-20 | Mauch Robert P. | +3,762 | $86.09 | $323,871 |
| 2026-02-18 | Mauch Robert P. | -1,333 | $359.46 | $479,160 |
| 2026-01-30 | Tyler Lauren M | +84 | $359.22 | $30,174 |
| 2026-01-30 | NALLY DENNIS M | +98 | $359.22 | $35,204 |
| 2026-01-30 | Cooper Ellen | +66 | $359.22 | $23,709 |
| 2026-01-30 | Cooper Ellen | +69 | $359.22 | $24,786 |
| 2026-01-20 | Mauch Robert P. | -3,763 | - | - |
| 2026-01-20 | Mauch Robert P. | -5,096 | $354.73 | $1,807,704 |
| 2026-01-20 | Mauch Robert P. | +3,763 | $86.09 | $323,957 |
| 2025-12-31 | Campbell Elizabeth S | +34 | $287.088 | $9,761 |
| 2025-12-31 | Battaglia Silvana | +27 | $287.088 | $7,751 |
| 2025-12-19 | Campbell Elizabeth S | -3,351 | $342.1 | $1,146,377 |
| 2025-12-19 | Battaglia Silvana | -1,677 | $345 | $578,565 |
| 2025-12-18 | Mauch Robert P. | -3,763 | - | - |
| 2025-12-18 | Mauch Robert P. | -5,096 | $343.45 | $1,750,221 |
| 2025-12-18 | Mauch Robert P. | +3,763 | $86.09 | $323,957 |
| 2025-12-17 | NALLY DENNIS M | -1,173 | - | - |
| 2025-12-17 | Mauch Robert P. | -3,000 | - | - |
| 2025-12-17 | Krikorian Lazarus | -4,031 | $343.235 | $1,383,580 |
| 2025-12-17 | Cleary James F | -45,154 | - | - |
| 2025-12-17 | Cleary James F | -26,952 | $344.145 | $9,275,396 |
| 2025-12-17 | Cleary James F | +45,154 | $86.09 | $3,887,308 |
| 2025-12-15 | Mauch Robert P. | -638 | - | - |
| 2025-12-15 | Mauch Robert P. | -638 | $350.32 | $223,504 |
| 2025-12-15 | Mauch Robert P. | +638 | - | - |
| 2025-12-15 | Krikorian Lazarus | -91 | - | - |
| 2025-12-15 | Krikorian Lazarus | -91 | $350.32 | $31,879 |
| 2025-12-15 | Krikorian Lazarus | +91 | - | - |
| 2025-12-15 | Cleary James F | -199 | - | - |
| 2025-12-15 | Cleary James F | -199 | $350.32 | $69,714 |
| 2025-12-15 | Cleary James F | +199 | - | - |
| 2025-11-20 | Campbell Elizabeth S | -1,590 | - | - |
| 2025-11-20 | Campbell Elizabeth S | -736 | $362.07 | $266,484 |
| 2025-11-20 | Campbell Elizabeth S | +1,590 | - | - |
| 2025-11-20 | Battaglia Silvana | -932 | - | - |
| 2025-11-20 | Battaglia Silvana | -406 | $362.07 | $147,000 |
| 2025-11-20 | Battaglia Silvana | +932 | - | - |
| 2025-11-20 | Verma Pawan | -1,974 | - | - |
| 2025-11-20 | Verma Pawan | -1,010 | $362.07 | $365,691 |
| 2025-11-20 | Verma Pawan | +1,974 | - | - |
| 2025-11-20 | Mauch Robert P. | -5,790 | - | - |
| 2025-11-20 | Mauch Robert P. | -2,144 | $362.07 | $776,278 |
| 2025-11-20 | Mauch Robert P. | +5,790 | - | - |
| 2025-11-20 | Krikorian Lazarus | -1,023 | - | - |
| 2025-11-20 | Krikorian Lazarus | -421 | $362.07 | $152,431 |
| 2025-11-20 | Krikorian Lazarus | +1,023 | - | - |
| 2025-11-20 | Cleary James F | -1,876 | - | - |
| 2025-11-20 | Cleary James F | -824 | $362.07 | $298,346 |
| 2025-11-20 | Cleary James F | +1,876 | - | - |
| 2025-11-18 | Mauch Robert P. | -3,763 | - | - |
| 2025-11-18 | Mauch Robert P. | -5,096 | $366.64 | $1,868,397 |
| 2025-11-18 | Mauch Robert P. | +3,763 | $86.09 | $323,957 |
| 2025-11-13 | Campbell Elizabeth S | -9,532 | $312.53 | $2,979,036 |
| 2025-11-13 | Campbell Elizabeth S | +20,613 | - | - |
| 2025-11-13 | Battaglia Silvana | -5,612 | $312.53 | $1,753,918 |
| 2025-11-13 | Battaglia Silvana | +12,885 | - | - |
| 2025-11-13 | Mauch Robert P. | -18,677 | $312.53 | $5,837,123 |
| 2025-11-13 | Mauch Robert P. | +42,944 | - | - |
| 2025-11-13 | Krikorian Lazarus | -1,059 | $312.53 | $330,969 |
| 2025-11-13 | Krikorian Lazarus | +2,434 | - | - |
| 2025-11-13 | Cleary James F | -13,901 | $312.53 | $4,344,480 |
| 2025-11-13 | Cleary James F | +30,062 | - | - |
| 2025-11-12 | Verma Pawan | +3,963 | - | - |
| 2025-11-12 | Campbell Elizabeth S | +3,523 | - | - |
| 2025-11-12 | Battaglia Silvana | +2,202 | - | - |
| 2025-11-12 | Mauch Robert P. | +15,960 | - | - |
| 2025-11-12 | Krikorian Lazarus | +2,271 | - | - |
| 2025-11-12 | Cleary James F | +4,733 | - | - |
| 2025-11-07 | Campbell Elizabeth S | -1,830 | - | - |
| 2025-11-07 | Campbell Elizabeth S | -2,023 | - | - |
| 2025-11-07 | Campbell Elizabeth S | -572 | $360.7 | $206,320 |
| 2025-11-07 | Campbell Elizabeth S | +1,830 | - | - |
| 2025-11-07 | Campbell Elizabeth S | -798 | $360.7 | $287,839 |
| 2025-11-07 | Campbell Elizabeth S | +2,023 | - | - |
| 2025-11-07 | Battaglia Silvana | -1,084 | - | - |
| 2025-11-07 | Battaglia Silvana | -1,265 | - | - |
| 2025-11-07 | Battaglia Silvana | -473 | $360.7 | $170,611 |
| 2025-11-07 | Battaglia Silvana | +1,084 | - | - |
| 2025-11-07 | Battaglia Silvana | -551 | $360.7 | $198,746 |
| 2025-11-07 | Battaglia Silvana | +1,265 | - | - |
| 2025-11-07 | Mauch Robert P. | -4,065 | - | - |
| 2025-11-07 | Mauch Robert P. | -4,215 | - | - |
| 2025-11-07 | Mauch Robert P. | -1,673 | $360.7 | $603,451 |
| 2025-11-07 | Mauch Robert P. | +4,065 | - | - |
| 2025-11-07 | Mauch Robert P. | -1,735 | $360.7 | $625,815 |
| 2025-11-07 | Mauch Robert P. | +4,215 | - | - |
| 2025-11-07 | Krikorian Lazarus | -1,398 | - | - |
| 2025-11-07 | Krikorian Lazarus | -1,433 | - | - |
| 2025-11-07 | Krikorian Lazarus | -366 | $360.7 | $132,016 |
| 2025-11-07 | Krikorian Lazarus | +1,398 | - | - |
| 2025-11-07 | Krikorian Lazarus | -411 | $360.7 | $148,248 |
| 2025-11-07 | Krikorian Lazarus | +1,433 | - | - |
| 2025-11-07 | Cleary James F | -2,439 | - | - |
| 2025-11-07 | Cleary James F | -2,951 | - | - |
| 2025-11-07 | Cleary James F | -705 | $360.7 | $254,294 |
| 2025-11-07 | Cleary James F | +2,439 | - | - |
| 2025-11-07 | Cleary James F | -1,250 | $360.7 | $450,875 |
| 2025-11-07 | Cleary James F | +2,951 | - | - |
| 2025-11-01 | NALLY DENNIS M | +104 | $337.81 | $35,132 |
| 2025-11-01 | Baumann Werner | +108 | $337.81 | $36,483 |
| 2025-11-01 | Tyler Lauren M | +89 | $337.81 | $30,065 |
| 2025-10-31 | Verma Pawan | -8,537 | - | - |
| 2025-10-31 | Verma Pawan | -4,367 | $337.81 | $1,475,216 |
| 2025-10-31 | Verma Pawan | +8,537 | $337.81 | $2,883,884 |
| 2025-10-20 | Mauch Robert P. | -3,763 | - | - |
| 2025-10-20 | Mauch Robert P. | -5,097 | $326.8 | $1,665,700 |
| 2025-10-20 | Mauch Robert P. | +3,763 | $86.09 | $323,957 |